|
Published by: Espicom Healthcare Intelligence
Published: Apr. 11, 2008 - 245 Pages
Table of Contents
- Blood Cancers
- US incidence of blood cancers, 2007
- Unmet Medical Need
- New Agents In Development
- New mechanisms of action under investigation for the development of blood cancers:
- Monoclonal antibodies in development for treatment of blood cancers
- Major Players
- 2007
- Market share of players in the worldwide blood cancers market, 2007
- 2012
- Market share of players in the worldwide blood cancers market, 2012
- Global Sales
- Estimated and forecast worldwide sales in the treatment of blood cancers (US$ millions)
- Regional breakdown of blood cancer market by sales - 2007 and 2012
- Chronic Lymphocytic Leukaemia
- Background
- Patient Statistics
- patient model
- Estimated prevalence of CLL in major markets, 2005-2012
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast CLL market growth (US$ millions)
- major players
- Current drugs commonly used in the treatment of CLL
- Major players in CLL by sales - 2007
- Forecast major players in CLL by sales - 2012
- The Drugs
- Current Drugs
- Selected response rates from studies of first line treatment of CLL:
- Fludara
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Fludara sales in CLL by region (US$ millions)
- Forecast Fludara sales in CLL by use (US$ millions)
- Competitor ratio analysis
- Rituxan
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Rituxan sales in CLL by use (US$ millions)
- Forecast Rituxan sales in CLL by region (US$ millions)
- Competitor ratio analysis
- Campath
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Campath sales in CLL by use (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of CLL
- Agents in late stage development for CLL:
- Treanda
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Treanda sales in CLL (US$ millions)
- Competitor ratio analysis
- Genasense
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Genasense in CLL efficacy summary:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Genasense sales in CLL by region (US$ millions):
- Forecast Genasense sales in CLL by use (US$ millions):
- Competitor ratio analysis
- Ofatumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast ofatumumab sales in CLL by region (US$millions):
- Forecast ofatumumab sales in CLL by use (US$millions):
- Competitor ratio analysis
- Alvocidib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast alvocidib sales in CLL (US$ millions)
- Competitor ratio analysis
- Lumliximab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast lumiliximab sales in CLL (US$ millions)
- Competitor ratio analysis
- Revlimid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Revlimid CLL sales by use (US$ millions):
- Forecast Revlimid CLL sales by region (US$ millions):
- Competitor ratio analysis
- Chronic Myeloid Leukaemia
- Background
- Patient Statistics
- Trends in US CML incidence:
- Estimated incidence in worldwide CML prevalence:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast worldwide CML market (US$ millions)
- major players - 2007
- Major players in CML by sales - 2007
- major players - 2012
- Forecast major players in CLL by sales - 2012
- The Drugs
- CML treatment timeline:
- Current drugs
- Current drugs used in the treatment of CML:
- Gleevec/Glivec
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- IRIS study: 18-Month Response Rates Determined by Intent-to-Treat Analysis
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Gleevec sales in CML (US$ millions) - excludes sales in GIST
- Competitor ratio analysis
- Sprycel
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Sprycel CML sales (US$ millions):
- Competitor ratio analysis
- Tasigna
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Tasigna CML sales forecast (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of CML:
- Agents in late stage development for CML:
- Bosutinib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast bosutinib sales in CML (US$ millions)
- Competitor ratio analysis
- Panobinostat
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- MK-0457/ VX 680
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Acute Myeloid Leukaemia
- Background
- French-American-British (FAB) Classification of AML
- WHO AML classification:
- Selected risk factors associated with AML:
- Common chromosomal abnormalities in AML:
- Patient Statistics
- Forecast incidence of AML by region:
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast worldwide adult AML market
- major players - 2007
- major players - 2012
- Forecast major players in AML by sales - 2012
- The Drugs
- Treatment naïve patients
- Relapsed & refractory AML
- Current drugs used in the treatment of AML:
- Therapeutic strategies in AML and relapsed/refractory AML:
- Mylotarg
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Summary of response rates in Mylotarg studies:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Agents in Development
- Agents in late stage development for AML:
- Clolar/Evoltra
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of Clolar/Evoltra in adult AML (US$ millions):
- Competitor ratio analysis
- Cloretazine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of Cloretazine in AML (US$ millions)
- Competitor ratio analysis
- Zarnestra
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Dacogen
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Dacogen sales in adult AML (US$ millions)
- Competitor ratio analysis
- lestaurtinib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast lestaurtinib sales in AML (US$ millions)
- Competitor ratio analysis
- midostaurin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast midostaurin sales in AML (US$ millions)
- Competitor ratio analysis
- tandutinib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- zosuquidar
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Xanafide
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Xanafide sales in AML (US$ millions)
- Competitor ratio analysis
- Ceplene
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Ceplene sales in AML (US$ millions)
- Competitor ratio analysis
- Multiple Myeloma
- Background
- Patient Statistics
- patient model
- Estimated prevalence of multiple myeloma in selected markets
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast worldwide multiple myeloma market (US$ millions):
- major players
- Major players in multiple myeloma by sales - 2007
- Major players in multiple myeloma by sales - 2012
- Current drugs used in the treatment of multiple myeloma:
- The Drugs
- Thalomid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Thalomid sales in multiple myeloma (US$ millions)
- Competitor ratio analysis
- Revlimid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Data summary of MM-009 and MM - 010 studies:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Front line myeloma comparison:
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Velcade
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Velcade sales in multiple myeloma (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of multiple myeloma:
- Agents in late stage development for multiple myeloma:
- Tanespimycin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast tanespimycin sales in relapsed/refractory multiple myeloma (US$ millions)
- Competitor ratio analysis
- mapatumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Belinostat
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Perifosine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Carfilzomib
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Non Hodgkin’s Lymphoma
- Background
- Frequency of NHL subtypes in adults:
- 1) B-cell Cll/small lymphocytic lymphoma
- 2) marginal zone lymphoma
- 3) lymphoplasmocytic lymphoma (Waldenstrom macroglobulinemia):
- 4) Follicular lymphoma:
- 1) Cutaneous t-cell lymphoma:
- 1) diffuse large B-cell lymphoma (dlBCl):
- 2) mantle cell lymphoma:
- 3) Burkitt lymphoma/Burkitt-like lymphoma:
- 4) precursor B-cell leukaemia/lymphoma
- 1) anaplastic large t/null-cell lymphoma:
- 2) precursor t-lymphoblastic lymphoma/leukaemia:
- 3) peripheral t-cell lymphomas:
- Staging Systems
- Patient Statistics
- patient model
- Forecast NHL incidence and prevalence (000s)
- Drug Growth Drivers
- Drug Growth Dampeners
- The Market
- Global market
- Forecast NHL market (excluding CTCL) - US$ millions
- Forecast CTCL market - US$ millions
- major players
- Current drugs commonly used in the treatment of NHL
- Major players in NHL by sales - 2007
- Major players in NHL by sales - 2012
- The Drugs
- Low Grade or Indolent NHL
- Treatment options in indolent/low-grade NHL:
- Intermediate- and high-grade lymphomas:
- T-cell lymphomas:
- Summary of common therapies in NHL
- Marketed Agents For Use In NHL
- Rituxan
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Rituxan penetration rates, Q3-Q4 2005
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Rituxan sales in NHL indications by region (US$ millions)
- Forecast Rituxan sales in NHL indications by use (US$ millions)
- Competitor ratio analysis
- Fludara
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Fludara sales in NHL indications (US$ millions)
- Competitor ratio analysis
- Bexxar
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Bexxar sales (US$ millions):
- Competitor ratio analysis
- Zevalin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Zevalin sales (US$ millions)
- Competitor ratio analysis
- Marketed Agents For Cutatenous T-Cell Lymphoma
- Zolinza
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Zolinza sales in CTCL (US$ millions)
- Competitor ratio analysis
- Agents in Development
- Drugs in development for the treatment of NHL:
- Agents in late stage development for NHL:
- Treanda
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Treanda US sales forecasts in NHL indication (US$ millions)
- Competitor ratio analysis
- ofatumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Phase I/II trial results summary:
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of ofatumumab in NHL by region (US$ millions):
- Forecast sales of ofatumumab in NHL by use (US$ millions):
- Competitor ratio analysis
- galiximab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast galiximab sales in NHL (US$ millions)
- Competitor ratio analysis
- pixantrone
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast pixantrone NHL sales by region (US$ millions):
- Forecast pixantrone sales in NHL by use (US$ millions)
- Competitor ratio analysis
- Revlimid
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Revlimid sales forecasts in NHL (US$ millions)
- Competitor ratio analysis
- Torisel
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Torisel sales in MCL (US$ millions)
- Competitor ratio analysis
- Velcade
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast Velcade sales in MCL (US$ millions)
- Forecast Velcade sales in follicular NHL (excludes MCL) by region (US$ millions)
- Forecast Velcade sales in follicular NHL (excludes MCL) by use (US$ millions)
- Competitor ratio analysis
- Inotuzumab Ozogamicin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- Agents In Late Stage Development For Cutaneous T-Cell Lymphoma
- Zanliumumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of zanolimumab in CTCL (US$ millions)
- Competitor ratio analysis
- belinostat
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of belinostat in CTCL (US$ millions)
- Competitor ratio analysis
- Fodosine
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Forecast sales of Fodosine in CTCL (US$ millions)
- Competitor ratio analysis
- Epratuzumab
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- enzastaurin
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor ratio analysis
- CRA Analysis: AML
- CRA summary
- CRA Analysis: CML
- CRA summary
- CRA Analysis: CLL
- CRA Analysis: Multiple Myeloma
- CRA Summary
- CRA Analysis: NHL
- CRA analysis - NHL
- CRA analysis - NHL (continued)…includes CTCL
- Acronyms
AbstractThis new strategic report from Espicom provides a comprehensive review of current and future treatments for major blood cancer therapy areas: chronic lymphocytic leukaemia, chronic myeloid leukaemia, acute myeloid leukaemia, multiple myeloma and non-Hodgkin's lymphoma. Over 275 pages
of product analysis, market statistics and forecasts
Unique market share and 5-year sales forecasts for leading products & pipeline prospects.
A comprehensive examination of major blood cancer therapy areas.
Critical competitive evaluation and scoring of current and future products.
Providing…
- Detailed analysis and 5-year forecasts for current leading products by value
- A detailed review and assessment of up and coming products
- Unique product assessment and scoring
- An evaluation of the current understanding of blood cancers
THE REPORT COVERS MAJOR BLOOD CANCER AREAS
- Chronic lymphocytic leukaemia
- Chronic myeloid leukaemia
- Acute myeloid leukaemia
- Multiple myeloma
- Non-Hodgkin’s lymphoma
THE MARKET
- Risk factors, how the disease affects patients, diagnosis and stages of the disease
- The market in 2007 and 2012
- Growth drivers and dampeners
PATIENT STATISTICS
- Prevalence
- Diagnosis rates
- Unmet clinical need
CURRENT TREATMENT OPTIONS
- Interventions by type
- Unique five point competitive assessment and scoring of current therapies and companies involved
- 5-year sales forecasts for key products
R&D: DRUGS IN LATE STAGE DEVELOPMENT
- Focus on new classes of drugs and the companies involved
- Unique competitive assessment and scoring of new therapies and companies involved
- 5-year sales forecasts for key products from year of launch
Get Full Details About This Report >>
|
